Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2018	Apr. 30, 2017
Revenue:
Sales			$ 2,218
Licensing income			700,000
Total Revenue			702,218
Operating expenses
Research and development	307,420	187,786	696,099	263,426
General and administrative	684,390	346,222	1,800,440	589,127
Total Operating Expenses	991,810	534,008	2,496,539	852,553
Operating Loss	(991,810)	(534,008)	(1,794,321)	(852,553)
Other Income/(Expense):
Interest expense	(149,590)	(186,463)	(426,780)	(429,971)
Changes in fair value of contingent purchase consideration (Note 8)	4,573,493	(49,537,836)	23,350,122	(49,537,836)
Impairment of goodwill				(14,335,822)
Change in fair value of derivative liabilities		1,034,991		709,917
Net Income (loss)	3,432,093	(49,223,316)	21,129,021	(64,446,265)
Net (loss) attributable to noncontrolling interests	(103,794)	(7,132,015)	(313,261)	(7,159,298)
Net (Loss) Available to Common Stockholders	$ 3,535,887	$ (42,091,301)	$ 21,442,282	$ (57,286,967)
Basic	$ 3.31	$ (45.83)	$ 20.08	$ (59.67)
Diluted	$ 3.31	$ (45.83)	$ 8.26	$ (59.67)
Basic	1,068,101	918,416	1,068,101	960,054
Diluted	2,592,716	918,416	2,592,716	960,054
Comprehensive Income :
Net Income	$ 3,535,887	$ (42,091,301)	$ 21,442,282	$ (57,286,967)
Change in foreign currency translation adjustments	13,677	5,560	9,779	14,073
Comprehensive Income Available to Common Stockholders	$ 3,549,564	$ (42,085,741)	$ 21,452,061	$ (57,272,894)